Literature DB >> 15170359

High-affinity binding of tumor-suppressor protein p53 and HMGB1 to hemicatenated DNA loops.

Michal Stros1, Eva Muselíková-Polanská, Sárka Pospísilová, François Strauss.   

Abstract

We have recently observed that chromatin architectural protein HMGB1 (previously reported to be involved in numerous biological processes such as DNA replication, recombination, repair, tumor growth, and metastasis) could bind with extremely high affinity (K(d) < 1 pM) to a novel DNA structure that forms a DNA loop maintained at its base by a hemicatenane (hcDNA). The loop of hcDNA contains a track of repetitive sequences derived from CA-microsatellites. Here, we report using a gel-retardation assay that tumor-suppressor protein p53 can also bind to hcDNA. p53 is a crucial molecule protecting cells from malignant transformation by regulating cell-cycle progression, apoptosis, and DNA repair by activation or repression of transcription of its target genes by binding to specific p53 DNA-binding sites and/or certain types of DNA lesions or alternative DNA structures. The affinity of p53 for hcDNA (containing sequences with no resemblance to the p53 DNA consensus sequence) is >40-fold higher (K(d) approximately 0.5 nM) than that for its natural specific binding sites within its target genes (Mdm2 promoter). Binding of p53 to hcDNA remains detectable in the presence of up to approximately 4 orders of magnitude of mass excess of competitor linear DNA, suggesting a high specificity of the interaction. p53 displays a higher affinity for hcDNA than for DNA minicircles (lacking functional p53-specific binding sequence) with a size similar to that of the loop within the hcDNA, indicating that the extreme affinity of p53 for hcDNA is likely due to the binding of the protein to the hemicatenane. Although binding of p53 to hcDNA occurs in the absence of the nonspecific DNA-binding extreme carboxy-terminal regulatory domain (30-C, residues 363-393), the isolated 30-C domain (but not the sequence-specific p53 "core domain", residues 94-312) can also bind hcDNA. Only the full-length p53 can form stable ternary complexes with hcDNA and HMGB1. The possible biological relevance of p53 and HMGB1 binding to hemicatenanes is discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15170359     DOI: 10.1021/bi049928k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  31 in total

1.  p53/HMGB1 complexes regulate autophagy and apoptosis.

Authors:  Kristen M Livesey; Rui Kang; Philip Vernon; William Buchser; Patricia Loughran; Simon C Watkins; Lin Zhang; James J Manfredi; Herbert J Zeh; Luyuan Li; Michael T Lotze; Daolin Tang
Journal:  Cancer Res       Date:  2012-02-16       Impact factor: 12.701

2.  Neuropeptide modulators of high mobility group box 1 secretion as potential therapeutic agents for severe sepsis.

Authors:  Mitchell P Fink
Journal:  Am J Pathol       Date:  2008-04-10       Impact factor: 4.307

3.  Nucleosome Crowding in Chromatin Slows the Diffusion but Can Promote Target Search of Proteins.

Authors:  Ryo Kanada; Tsuyoshi Terakawa; Hiroo Kenzaki; Shoji Takada
Journal:  Biophys J       Date:  2019-05-11       Impact factor: 4.033

Review 4.  Transcriptional regulation by p53.

Authors:  Rachel Beckerman; Carol Prives
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-28       Impact factor: 10.005

Review 5.  High-mobility group box 1, oxidative stress, and disease.

Authors:  Daolin Tang; Rui Kang; Herbert J Zeh; Michael T Lotze
Journal:  Antioxid Redox Signal       Date:  2011-04-01       Impact factor: 8.401

Review 6.  Senescent cells as a source of inflammatory factors for tumor progression.

Authors:  Albert R Davalos; Jean-Philippe Coppe; Judith Campisi; Pierre-Yves Desprez
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

7.  Prediction of a gene regulatory network linked to prostate cancer from gene expression, microRNA and clinical data.

Authors:  Eric Bonnet; Tom Michoel; Yves Van de Peer
Journal:  Bioinformatics       Date:  2010-09-15       Impact factor: 6.937

Review 8.  Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.

Authors:  Marianela Candolfi; Kurt M Kroeger; A K M G Muhammad; Kader Yagiz; Catherine Farrokhi; Robert N Pechnick; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

Review 9.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

Review 10.  Single proteins might have dual but related functions in intracellular and extracellular microenvironments.

Authors:  Derek C Radisky; Melody Stallings-Mann; Yohei Hirai; Mina J Bissell
Journal:  Nat Rev Mol Cell Biol       Date:  2009-02-04       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.